The Correlation Between The Expression Of ER, PR, Ps2, C-erbB-2 And The Effective Rate Of Neoadjuvant Chemotherapy In Breast Cancer

Research ContextNeoadjuvant chemotherapy for breast cancer carried out in the 20th century,70s, Haagensen and Stout first proposed the concept of neoadjuvant chemotherapy. Neoadjuvant chemotherapy is a major part of the current multidisciplinary treatment of breast cancer in the increasingly widespread application of breast cancer, locally advanced breast cancer treatment has become a new trend. Pathological examination of biopsy specimens before surgery to provide a basis for early diagnosis of breast cancer, but also for the study to determine the efficacy of biological indicators of tumor basis. Breast cancer is a hormone dependent tumor, estrogen and progesterone by regulation, the majority of breast cancer have their receptor expression in breast cancer there is most of proto-oncogene C-erbB-2 expression. Breast Cancer ER, PR and C-erbB-2 expression and the biological behavior and pathological features and prognosis of this clinical choice is chemotherapy, surgery type, and assessment of important prognostic indicators. In recent years, awareness of breast cancer found Ps2 on the biological behavior and clinical endocrine hormone-dependent treatment is important, some scholars believe that as a predictor of endocrine therapy for breast cancer, its role may be better than ER and PR.ObjectiveTo investigate the relationship between the expression of ER, PR, Ps2 and Her-2 and the effective rate of neoadjuvant chemotherapy in breast cancer.MethodsImmunohistochemical method was used to detect the expression of ER, PR, Ps2 and C-erbB-2 in 50 breast cancer which received neoadjuvant chemotherapy.ResultsThe effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups (83.3% vs59.4%,82.4%vs60.6%) (P<0.05);compared C-erbB-2 overexpression over-expression group and the group of non-efficient between the results of chemotherapy Difference was not statistically significant (81.8%vs64.1%)(P> 0.05)and the same thing happen between Ps2 negative group and Ps2 positive group(67.7% vs63.2%) (P>0.05)ConclusionER,PR negative breast cancer patients more sensitive to neadjuvant chemotherapy, these patients are chemotherapybenefited more. ER, PR can be used as neoadjuvant chemotherapy in breast cancer prediction indicators.